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            INTRODUCTION 
 
The  latest world health organization (WHO) reports show that there were 9.0 million 
new tuberculosis (TB) cases and 1.5 million tuberculosis (TB) deaths, leading cause of death 
from an infectious disease worldwide, after the human immunodeficiency virus (HIV). Co-
infection with the HIV fuels the global TB crisis, and successful TB treatment is further 
complicated and hampered by the existence of multidrug- resistant (MDR) TB and extensively 
drug resistant (XDR) TB 
[1] 
Tuberculosis, MTB, or TB (short for tubercle bacillus), in the past also called phthisis, 
phthisis pulmonalis, or consumption, is a widespread, infectious disease caused by various 
strains of mycobacteria, usually Mycobacterium tuberculosis. Tuberculosis generally affects the 
lungs, but can also affect other parts of the body. [2]
 
                                             
 
                                             Fig 1: Mycobacterium tuberculosis 
 
One-third of the world's population is thought to have been infected with M. tuberculosis, 
and new infections occur in about 1% of the population each year. In 2007, an estimated 13.7 
million chronic cases were active globally, while in 2013, an estimated 9 million new cases 
occurred
. 
In 2013 there were between 1.3 and 1.5 million associated deaths
 [2], 
most of which 
occurred in developing countries
.
 The total number of tuberculosis cases has been decreasing 
since 2006, and new cases have decreased since 2002
.
 Many people in the developing world 
contract tuberculosis because of a poor immune system, largely due to high rates of HIV 
infection and the corresponding development of AIDS.
 [1] 
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HISTORY 
 
Tuberculosis has been present in humans since antiquity 
[3].
 The earliest 
detection of M. tuberculosis involves evidence of the disease in the remains of bison in 
Wyoming dated to around 17,000 years ago 
[4].
 However, whether tuberculosis originated 
in bovines, then was transferred to humans, or whether it diverged from a common 
ancestor, is currently unclear 
[5].
 A comparison of the genes of M. tuberculosis complex 
(MTBC) in humans to MTBC in animals suggests humans did not acquire MTBC from 
animals during animal domestication, as was previously believed. Both strains of the 
tuberculosis bacteria share a common ancestor, which could have infected humans as 
early as the Neolithic Revolution
.[5]
 
           
                                           
                   Fig 2: Natural History of TB infection 
 
Phthisi is a Greek word for consumption, an old term for pulmonary tuberculosis; 
around 460 BC, Hippocrates described phthisis as a disease of dry seasons
. [6]
 
 
Although the pulmonary form associated with tubercles was established as a 
pathology by Dr. Richard Morton in 1689 
[5] [6],
 due to the variety of its symptoms, TB 
was not identified as a single disease until the 1820s. It was not named "tuberculosis" 
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until 1839, by J. L. Schönlein
.[7][8]. 
The bacillus causing tuberculosis, M. tuberculosis, was 
identified and described on 24 March 1882 by Robert Koch.
[12] 
          
Albert Calmette and Camille Guérin achieved the first genuine success in immunization 
against tuberculosis in 1906, using attenuated bovine-strain tuberculosis. It was called bacille 
Calmette–Guérin (BCG). The BCG vaccine was first used on humans in 1921 in France[11], but 
received widespread acceptance in the US, Great Britain, and Germany only after World War 
II
.[12]
  
 
TYPES OF TUBERCULOSIS 
          Tuberculosis is a contagious disease; it affects almost all the important organs of the body. 
Clinically, tuberculosis is broadly categorized into three major categories 
 
1. Primary tuberculosis. 
2. Secondary tuberculosis. 
3. Disseminated tuberculosis. 
 
Primary tuberculosis: 
 
When tuberculosis affects a person who had never been exposed to the bacterium earlier, the 
condition is called primary tuberculosis. In this form of tuberculosis the source of bacterium is 
external
.[9] 
 
Secondary tuberculosis: 
 
It is also known as post primary tuberculosis. This type of tuberculosis occurs in a person 
who previously had TB. In primary TB, the bacterium goes into an inactive face while in 
secondary TB the bacterium regain its active mode and causes the symptom
[9].
 Secondary 
tuberculosis more infectious than primary TB. Secondary TB increases the chance of the 
infections spread to other organs such as kidneys, heart, and brain. 
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Disseminated tuberculosis: 
 
             Disseminated means that the tuberculosis has infected the entire body system. It is a very 
rare type of disease. It primarily affects the bones of spines, hips, joints and knees and even the 
central nervous system. It infect the CSF, the GIT, the adrenal gland, skin of the neck and even 
the heart
.[10]
 
 
CELL WALL  
 
          The well - developed cell wall contains a considerable amount of a fatty acid, mycolic 
acid, covalent attached to the underlying peptidoglycan-bound polysaccharide arabinogalactan, 
providing an extraordinary lipid barrier. This barrier is responsible for many of the medically 
challenging physiological characteristics of tuberculosis. The composition and quality of the cell 
wall components affect the bacteria’s virulence and growth rate.  
 
          The peptidoglycan polymer confers cell wall rigidity and just external to the bacterial cell 
membrane, another contributor to the permeability barrier of mycobacteria. The peptidoglycan 
polymer confers cell wall rigidity and is just external to the bacterial cell membrane, another 
contributor to the permeability barrier of mycobacteria.  
 
          Another important component of the cell wall is lipoarabinomannan, a carbohydrate 
structural antigen on the outside of the organism that is immunogenic and facilitates the survival 
of mycobacteria within macrophages. The cell wall is key to the survival of mycobacteria, and a 
more complete understanding of the biosynthetic pathways and gene functions and the 
development of antibiotics to prevent formation of the cell wall are areas of great interest
.[11]
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                                                     Fig 3: mycobacterial cell wall 
 
Pathogenesis of tuberculosis: 
    
           In the lungs, M. tuberculosis is taken up by alveolar macrophages, but they are unable to 
digest the bacterium. Its cell wall prevents the fusion of the phagosome with a lysosome. 
Specifically, M. tuberculosis blogs the bridging molecule, early endosomal auto antigen 
1(EEA1); however, this blockade does not prevent fusion of vesicle filled with nutrients. 
Consequently, the bacteria multiply unchecked with in the macrophages. The bacteria also 
carried the UreC gene, which prevents acidification of the phagosome. The bacteria also evade 
macrophages-killing by neutralizing reactive nitrogen intermediates. 
[11]
 
 
           M. tuberculosis usually enters the alveolar passages of exposed humans in an aerosol 
droplet, were its first contact is thought be with resident macrophages, but it is also possible that 
bacteria can be initially ingested by alveolar epithelial type II pneumocystis this cell type is 
found in greater numbers than macrophages in alveoli, and M. tuberculosis can infect and grow 
in this pneumocystis ex vivo.
[12] 
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         The bacteria are phagocytized in a process that is initiated by bacterial contact with 
macrophage mannose and/or complement receptors. Surfactant protein A, a glycoprotein found 
on alveolar surface, can enhance the binding and uptake of M. tuberculosis by up regulating 
mannose receptor activity.
[13]
  
         
On the other hand surfactant protein D, similarly located in alveoli, inhibits phagocytosis of M. 
tuberculosis by blocking mannosyl oligosaccharide residues on the bacterial cell surface, and it is 
proposed that this prevents M. tuberculosis interaction with mannose receptor on the 
macrophages cell surface. The human toll-like receptor 2 (TLR2) also plays a role in M. 
tuberculosis uptake. On entry in  to host macrophages, M. tuberculosis resides in an endocytic 
vacuole called the phagosome. If the normal phagosomal maturation cycle occurs.           
 
                        
     
       Fig 4: pathogenesis of tuberculosis 
 
Pulmonary 
If a tuberculosis infection does become active, it most commonly involves the 
lungs (in about 90% of cases). Symptoms may include chest pain and a prolonged cough 
producing sputum. About 25% of people may not have any symptoms (i.e. they remain 
"asymptomatic"). The upper lung lobes are more frequently affected by tuberculosis than 
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the lower ones.  The reason for this difference is not entirely clear. It may be due either to better 
air flow, or to poor lymph drainage within the upper lungs.
 [15] 
                                                   
 
                                                     Fig 6: Pulmonary Tuberculosis 
Extrapulmonary 
 In 15–20% of active cases, the infection spreads outside the lungs, causing other kinds of 
TB. These are collectively denoted as "extrapulmonary tuberculosis". Extrapulmonary TB occurs 
more commonly in immunosuppressed persons and young children. In those with HIV, this 
occurs in more than 50% of cases
[16]
. A potentially more serious, widespread form of TB is 
called "disseminated" TB, commonly known as miliary tuberculosis. Miliary TB makes up about 
10% of extrapulmonary cases.
[17]
  
 
MECHANISM                                                                                                                                                                   
 
Transmission 
        When people with active pulmonary TB cough, sneeze, speak, sing, or spit, they expel 
infectious aerosol droplets 0.5 to 5.0 µm in diameter. A single sneeze can release up to 40,000 
droplets. Each one of these droplets may transmit the disease, since the infectious dose of 
tuberculosis is very small (the inhalation of fewer than 10 bacteria may cause an infection).
 [18]
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Transmission should occur from only people with active TB – those with latent infection are not 
thought to be contagious. The probability of transmission from one person to another depends 
upon several factors, including the number of infectious droplets expelled by the carrier, the  
effectiveness of ventilation, the duration of exposure, the virulence of the M. tuberculosis strain, 
the level of immunity in the uninfected person, and others.
 [19] 
Diagnosis 
       Diagnosing active tuberculosis based merely on signs and symptoms is difficult, as is 
diagnosing the disease in those who are immunosuppressed. A diagnosis of TB should, however, 
be considered in those with signs of lung disease or constitutional symptoms lasting longer than 
two weeks. A chest X-ray and multiple sputum cultures for acid-fast bacilli are typically part of 
the initial evaluation.
 
Interferon-γ release assays and tuberculin skin tests are of little use in the 
developing world. IGRA have similar limitations in those with HIV.
[20]
leic acid amplification 
tests and adenosine deaminase testing may allow rapid diagnosis of TB. These tests, however, 
are not routinely recommended, as they rarely alter how a person is treated. Blood tests to detect 
antibodies are not specific or sensitive, so they are not recommended 
 
.         
                                         
 
                                       Fig 7: Tuberculosis diagnosis 
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Active tuberculosis 
 
It is spread through the air when people who have an active TB infection cough, sneeze, 
or otherwise transmit respiratory fluids through the air.  
The classic symptoms of active TB infection are a chronic cough with blood-tinged 
sputum, fever, night sweats, and weight loss (the last of these giving rise to the formerly 
common term for the disease, "consumption"). Infection of other organs causes a wide range of 
symptoms. 
[21]
 Diagnosis of active TB relies on radiology (commonly chest X-rays), as well as 
microscopic examination and microbiological culture of body fluids.  
Latent tuberculosis 
 
         Most infections do not have symptoms, known as latent tuberculosis. About one in ten 
latent infections eventually progresses to active disease which, if left untreated, kills more than 
50% of those so infected. 
 
                                   
                                                 Fig 8: Latent tuberculosis 
         Diagnosis of latent TB relies on the tuberculin skin test (TST) and/or blood tests. Treatment 
is difficult and requires administration of multiple antibiotics over a long period of time. 
Household, workplace, and social contacts are also screened and treated if necessary. Antibiotic 
resistance is a growing problem in multiple drug-resistant tuberculosis (MDR-TB) infections. 
Prevention relies on early detection and treatment of cases and on screening programs and 
vaccination with the bacillus Calmette-Guérin
[22]
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Mantoux tuberculin skin test 
         The Mantoux tuberculin skin test is often used to screen people at high risk for TB. Those 
who have been previously immunized may have a false-positive test result. Interferon gamma 
release assays (IGRAs), on a blood sample, are recommended in those who are positive to the 
Mantoux test. These are not affected by immunization or most environmental mycobacteria, so 
they generate fewer false-positive results.  
Prevention 
         Tuberculosis prevention and control efforts primarily rely on the vaccination of infants and 
the detection and appropriate treatment of active cases. The World Health Organization has 
achieved some success with improved treatment regimens, and a small decrease in case numbers 
 
                                    
 
                                                            Fig 9:   Prevention of disease         
Vaccines 
The only available vaccine as of 2011 is Bacillus Calmette-Guérin (BCG). In 
children it decreases the risk of getting the infection by 20% and the risk of infection 
turning into disease by nearly 60%. It is the most widely used vaccine worldwide, with 
more than 90% of all children being vaccinated. The immunity it induces decreases after 
about ten years. A number of new vaccines are currently in development. 
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Prognosis 
[23] 
Progression from TB infection to overt TB disease occurs when the bacilli overcome the 
overcome the immune system defenses and begin to multiply. In primary TB disease (some 1–
(some 1–5% of cases), this occurs soon after the initial infection. However, in the majority of 
cases, a latent infection occurs with no obvious symptoms.  
                                           
                                         
                                            Fig 10: Progression of Tuberculosis 
 
           The risk of reactivation increases with immunosuppression, such as that caused by 
infection with HIV. In people co-infected with M. tuberculosis and HIV, the risk of reactivation 
increases to 10% per year. Studies using DNA fingerprinting of M. tuberculosis strains have 
shown reinfection contributes more substantially to recurrent TB than previously thought, with 
estimates that it might account for more than 50% of reactivated cases in areas where TB is 
common. The chance of death from a case of tuberculosis is about 4% as of 2008, down from 8% 
in 1995.  
Epidemiology 
[24][25] 
            Roughly one-third of the world's population has been infected with M. tuberculosis , with 
new infections occurring in about 1% of the population each year. In 2010, 8.8 million new cases 
of TB were diagnosed, and 1.20–1.45 million deaths occurred, most of these occurring in 
developing countries. Of these 1.45 million deaths, about 0.35 million occur in those also 
infected with HIV.  
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Tuberculosis is the second-most common cause of death from infectious disease 
(after those due to HIV/AIDS). The number of new cases has declined by 17% between 
2004–2014. Hopes of totally controlling the disease have been dramatically dampened 
because of a number of factors, including the difficulty of developing an effective 
vaccine, the expensive and time-consuming diagnostic process, the necessity of many 
months of treatment, the increase in HIV-associated tuberculosis. India had the largest 
total incidence, with an estimated 2.0 million new cases.  
 
           The rate of TB varies with age. TB is mainly a disease of older people and the immune 
compromised (risk factors are listed above). Worldwide, 22 "high-burden" states or countries 
together experience 80% of cases as well as 83% of deaths.  
                                         
                                               Fig 11: Epidemiology of tuberculosis 
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    GLUTAMINE SYNTHETASE 
 
Glutamine synthetase is an enzyme that plays an essential role in the metabolism of 
nitrogen by catalyzing the condensation of glutamate and ammonia to form glutamine:
[26] 
 
                 Glutamate + ATP + NH3 → Glutamine + ADP + phosphate 
 
 
             
 
       Fig.12. Glutamine synthetase 
 
           Glutamine synthetase (GS; EC 6.3.1.2, also known as γ-glutamyl: ammonia Ligase) 
catalyzes the adenosine 5´-triphosphate (ATP) dependent condensation between glutamate and 
ammonia, to give glutamine. There are three types of GS, each with a different structure. These 
enzymes are present in all organisms; eukaryotes express GS type II while prokaryotes mainly 
express GS types I and III. All GS enzymes have an amino-acid binding site as well as a 
nucleotide-binding site. They also have three metal ions in the active site between the two 
pockets, which are necessary for stability and catalytic activity. The amino-acid-binding site is 
fairly well preserved amongst species, but the nucleotide-binding site differs between 
mammalian and bacterial enzymes. The focus of the work presented in this thesis was on the GS 
enzyme of M. tuberculosis.  
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First, the ATP molecule enters the nucleotide-binding site. Then glutamate enters 
from the opposite direction into the amino-acid-binding site. The γ-carboxylate of 
glutamate will then coordinate to either magnesium or manganese ions, and the γ-
phosphate of the ATP is transferred to the glutamate. The ammonium ion (NH4+) enters 
the active site and is deprotonated by an asparagine followed by an attack on the γ-
carbonyl. This will release the phosphate (PO43-), and glutamine is formed. 
[27] 
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MECHANISM  
 
            GS catalyzes the ATP dependent condensation of glutamate with ammonia to yield 
glutamine. The hydrolysis of ATP drives the first step of a two part, concerted mechanism. ATP 
phosphorylates glutamate to form ADP and an acyl phosphate intermediate, γ-glutamyl 
phosphate, which reacts with ammonia, forming glutamine and inorganic phosphate. ADP and Pi 
do not dissociate until ammonia binds and glutamine is released. ATP binds first to the top of the 
active site, glutamate binds near the second cation binding site at the bottom of the active site. 
The presence of ADP causes a conformational shift in GS that stabilizes the γ-glutamyl 
phosphate moiety. Ammonium binds strongly to GS only if the acylphosphate intermediate is 
present. Ammonium, rather than ammonia, binds to GS because the binding site is polar and 
exposed to solvent. In the second step, deprotonation of ammonium allows ammonia to attack 
the intermediate from its nearby site to form glutamine. Phosphate leaves through the top of the 
active site, while glutamine leaves through the bottom (between two rings). 
[28] 
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NEED TO FOCUS ON TUBERCULOSIS DISEASE 
 
 Tuberculosis is a leading cause of death worldwide. 
 
 In the year 2000-2005, there were around 10 to 15 million people with latent TB in the 
U.S & in 2007, 2.4 million cases were reported. 
 
 In the year 2010, WHO estimated that one-third of the world’s population (two billion 
people) was infected with the bacilli. Of the two billion people, approximately 9.8 million 
people will develop active tuberculosis and 2.6 million people will die per annum. 
 
  In the year 2013, approximately 13.7 million chronic active cases globally and In the 
year 2014, approximately 560 thousand new cases per year and 740 thousand new patients 
infected by both MTB and HIV due to multidrug-resistant Tuberculosis. 
 
NEED FOR NOVEL ANTI-TUBERCULOSIS AGENTS 
 
 A number of once active anti-tuberculosis drugs have now became inactive due to the 
ever increasing rise in drug resistant strains of tuberculosis. The reason for this is poor 
patient compliance which leads to the development of more drug resistant strains. 
 
 The lack in patient compliance is due to the fact that the current treatment regimen lasts 
6-9 months. The length of the treatment period makes difficulty in killing off the latent 
and slow-growing bacteria. Drug-resistant TB is a major public health concern. 
 
 
 The multi -drug resistant TB (MDR-TB) occurs only when drug-susceptible TB is 
improperly or incompletely treated. According to the World Health Organization(WHO), 
MDR-TB is defined as a resistance to two of the most effective first line TB agents: 
Rifampicin and isoniazid. When a strain of TB becomes resistance to any 
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fluoroquinolone and at least one of the three second-line agents (capreomycin, kanamycin 
and amikacin), it becomes described at extensively drug-resistant TB(XDR-TB) 
 
 Emergence of Multi-resistant(MDR) strains and high susceptibility of human 
immunodeficiency virus (HIV) infected persons to the disease forced the scientist to 
develop novel anti-tuberculosis agents. 
 
 It is evident by these facts; there is an ever growing need to develop novel agents for the 
treatment of tuberculosis. These new  agents should be potent, fast acting, have an 
excellent pharmacodynamics / pharmacokinetics (PK/PD) profile and have high 
therapeutic index, and preferably have a novel mechanism of action as to avoid cross-
resistant with other agents. 
 
MEDICINAL CHEMISTRY
[29] 
 
Medicinal chemistry is the science that deals with the discovery and design of 
new therapeutic chemicals and their development into useful medicines. Medicinal 
chemistry may involve synthesis of new molecules, investigation of the relationships 
between the structure of synthetic compounds and their biological activities, elucidations 
of their interactions with receptors of various kinds, including enzymes and DNA, the 
determination of their absorption, transport and distribution properties and studies of the 
metabolic transformations of these chemicals into other chemicals and their excretion. 
The drug discovery process involves designing, synthesizing, characterization and 
evaluation of new chemical entities, suitable for therapeutic use. It also includes study of 
existing drugs, their biological properties and their quantitative structural activity 
relationship (QSAR).  
 
DRUG DESIGN
[30] 
 
             Drug discovery process involves a rapid search for a small molecule often called as lead. 
A lead molecule is chemical compound which possess pharmacological or biological activity. 
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Sources of lead compounds can come from natural sources, such as plants, animals, or fungi and 
also from synthetic chemical libraries. 
 
LEAD OPTIMIZATION
[31] 
 
             Newly invented pharmacologically active moieties may have poor drug-likeness and 
may require lead optimization step. This step involves chemical modification of a lead in order to 
improve their potency, selectively towards binding site, pharmacokinetic parameters and reduced 
toxicity.  
 
COMPUTER AIDED DRUG DESIGN
[32] 
 
             The latest breakthroughs in computer-aided drug design, drug delivery systems, and 
enabling technologies. Computer Aided Drug Design (CADD) and Delivery Systems offers an 
in-depth discussion of the computer-assisted techniques used to discover, design, and optimize 
new, effective, and safe drugs.  
 
             Drug design, sometimes referred to as rational drug design or simply rational design, is 
the inventive process of finding new medications based on the knowledge of a biological target. 
The drug is most commonly an organic small molecule that activates or inhibits the function of a 
biomolecule such as a protein.  
             Drug design frequently but not necessarily relies on computer modeling techniques. This 
type of modeling is often referred to as computer-aided drug design. Finally, drug design that 
relies on the knowledge of the three-dimensional structure of the biomolecular target is known as 
structure-based drug design. In addition to small molecules, biopharmaceuticals and especially 
therapeutic antibodies are an increasingly important class of drugs and computational methods 
for improving the affinity, selectivity, and stability of these protein-based therapeutics have also 
been developed.  
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Furthermore, in vitro experiments complemented with computation methods are 
increasingly used in early drug discovery to select compounds with more favorable 
(absorption, distribution, metabolism, and excretion) and toxicological profiles. 
 
                                        
             
                                                   Fig13: drug discovery cycle 
 
Rational drug discovery
[33]
  
In contrast to traditional methods of drug discovery (known as forward 
pharmacology), which rely on trial-and-error testing of chemical substances on cultured 
cells or animals, and matching the apparent effects to treatments, rational drug design 
(also called reverse pharmacology) begins with a hypothesis that modulation of a specific 
biological target may have therapeutic value.  
 
The search for small molecules that bind to the target is begun by screening 
libraries of potential drug compounds. This may be done by using the screening assay (a 
"wet screen"). In addition, if the structure of the target is available, a virtual screen may 
be performed of candidate drugs. Several methods are available to estimate drug likeness 
such as Lipinski's Rule of Five and a range of scoring methods such as lipophilic 
efficiency. Several methods for predicting drug metabolism have also been proposed in 
the scientific literature.  
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Drug design with the help of computers may be used at any of the following stages of 
drug discovery:
[34]
 
1. Hit identification using virtual screening (structure- or ligand-based design) 
2. Hit-to-lead optimization of affinity and selectivity (structure-based design, QSAR, etc.) 
3. lead optimization of other pharmaceutical properties while maintaining affinity 
 
 
TYPES 
[35] 
 
            Drug discovery cycle highlighting both ligand-based (indirect) and structure-based 
(direct) drug design strategies. 
            There are two major types of drug design. The first is referred to as ligand-based drug 
design and the second, structure-based drug design.  
 
Ligand-based 
            Ligand-based drug design (or indirect drug design) relies on knowledge of other 
molecules that bind to the biological target of interest. These other molecules may be used to 
derive a pharmacophore model that defines the minimum necessary structural characteristics a 
molecule must possess in order to bind to the target.
  
 
In other words, a model of the biological target may be built based on the knowledge of what 
binds to it, and this model in turn may be used to design new molecular entities that interact with 
the target.  
 
Alternatively, a quantitative structure -activity relationship (QSAR), in which a correlation 
between calculated properties of molecules and their experimentally determined biological 
activity, may be derived. These QSAR relationships in turn may be used to predict the activity of 
new analogs.
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Structure-based 
            Structure-based drug design (or direct drug design) relies on knowledge of the three 
dimensional structure of the biological target obtained through methods such as x-ray 
crystallography or NMR spectroscopy. Using the structure of the biological target, candidate 
drugs that are predicted to bind with high affinity and selectivity to the target may be designed 
using interactive graphics and the intuition of a medicinal chemist.  
 
           Current methods for structure-based drug design can be divided roughly into three main 
categories.  
 
           The first method is identification of new ligands for a given receptor by searching large 
databases of 3D structures of small molecules to find those fitting the binding pocket of the 
receptor using fast approximate docking programs. This method is known as virtual screening. 
 
      A second category is de novo design of new ligands. In this method, ligand molecules 
are built up within the constraints of the binding pocket by assembling small pieces in a stepwise 
manner. These pieces can be either individual atoms or molecular fragments. The key advantage 
of such a method is that novel structures, not contained in any database, can be suggested. 
 
             A third method is the optimization of known ligands by evaluating proposed analogs 
within the binding cavity.  
 
Binding site identification 
              Binding site identification is the first step in structure based design. If the structure of 
the target or a sufficiently similar homolog is determined in the presence of a bound ligand, then 
the ligand should be observable in the structure in which case location of the binding site is 
trivial.  
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Scoring functions 
        
       One early general-purposed empirical scoring function to describe the binding energy of 
ligands to receptors was developed by Böhm. This empirical scoring function took the form: 
Where: 
 ΔG0 – empirically derived offset that in part corresponds to the overall loss of 
translational and rotational entropy of the ligand upon binding. 
 
 ΔGhb – contribution from hydrogen bonding 
 
 ΔGionic – contribution from ionic interactions 
 
 ΔGlip – contribution from lipophilic interactions where |Alipo| is surface area of lipophilic 
contact between the ligand and receptor 
 
 ΔGrot – entropy penalty due to freezing a rotatable in the ligand bond upon binding 
          A more general thermodynamic "master" equation is as follows:
[36] 
 
                 
 
Where: 
 desolvation – enthalpic penalty for removing the ligand from solvent 
 
 motion – entropic penalty for reducing the degrees of freedom when a ligand binds to its 
receptor 
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 configuration – conformational strain energy required to put the ligand in its "active" 
conformation 
 
 interaction – enthalpic gain for "resolvating" the ligand with its receptor 
 
 According to Gibbs free energy equation, the relation between dissociation equilibrium constant, 
Kd, and the components of free energy was built. 
The divergent development of tuberculosis as a disease means that easily accessible and 
effective diagnostic tools are extremely important in identifying possible transmission 
vectors as well as funneling treatment to the populations in most dire need.  
 
 
IN-SILICO DRUG DESIGN 
 
                      
 
Fig 14: In-silico drug design 
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DOCKING 
               
  Docking program is used to fit the ligand molecule into the target structure in a variety 
of position, conformations and orientations. Docking mode is known as pose. Each pose scored 
based on its complementarity to the target in terms of shape and properties such as electrostatics 
in order to identify the most favorable energetical pose.  
 
              The quality of any docking results depends on the starting structure of both the protein 
and the potential ligand. The protein and ligand structure need to be prepared to achieve the best 
docking results. 
 
 
PROTEIN PREPARATION 
 
It is now accepted that the old idea of the “key and lock” interaction of a ligand and its 
protein. Receptor is not an accurate description of most biological complexes. The ligand-protein 
interactions resemble more a “hand and glove” association, where both parts are flexible and 
adjust to complement each other induced fit. The can modify their shape and mould their 
complementarity. So, as to increase favorable contacts and reduced adverse interactions, 
maximizing the total binding free energy. It has been found that active site regions of enzymes 
appear to present areas of both low and high conformational stability. 
 
 
RECEPTOR CONFORMATION 
 
` The three dimensional (3-D) structures of both ligand and protein are necessary for the 
application of docking techniques. While the manifold of conformational structures of small 
molecule may be relatively easy to predict, the lowest energy conformation obtained may not 
correspond to that of the bound ligand.  
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  Many proteins targeted for drug design do not have an experimentally 
determined structure and, therefore, docking studied cannot be performed directly. In 
some cases, computational techniques can be used to predict the 3D structure of a protein 
provided the structure of a closely related protein homolog is known. Homology 
modeling or sequence threading techniques may be used to generate models of protein 
structure which, although not as good as experimentally determined structures, can be 
used as docking targets.                 
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                                                   AIM AND OBJECTIVE 
 
 
AIM 
 
           The aim of this project is to design molecules into potential anti-tubercular activity 
that is capable of inhibiting cell wall synthesis by inhibiting glutamine synthetase. The 
designed compounds will be synthesized, characterized and evaluated for activity and 
toxicity.     
 
OBJECTIVE 
        
     The compounds are designed and docked against a specific crucial target, Glutamine 
Synthetase I, which is involved in the cell wall biosynthesis and nitrogen metabolism. The 
synthesized compounds are expected to act on the same.  
 
DESIGN 
 
           In-silico design of glutamine synthetase 1 inhibitors. 
 
SYNTHESIS 
 
           A novel anti-tubercular activity containing compounds are synthesized under specific 
conditions, which is effective against specific microbes. 
 
 
CHARACTERIZATION 
 
 The above synthesized compounds will be identified and characterized by following 
methods 
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 Melting point 
 
 TLC method 
 
 Infrared Spectroscopy 
 
 Nuclear Magnetic Resonance 
 
 Mass spectroscopy 
 
 Gas Chromatography and Mass Spectroscopy (GC-MS) and if necessary 
 
 Liquid Chromatography and Mass Spectroscopy (LC-MS) 
 
 
BIOLOGICAL EVALUATION 
 
The synthesized compounds will be screened for their anti-tubercular activity 
by in-vitro methods. 
 
 
TOXICOLOGICAL PREDICTION 
 
 Toxicological prediction will be carried out for synthesized compounds by 
in-silico property explorer like OSIRIS. 
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                 The present study will be conducted  according to the following design 
 
                                            
 
             
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                             
 
 
 
                   IDENTIFICATION OF BASIC STRUCTURE 
STRUCTURAL MODIFICATION OF BASIC NUCLEUS  
DOCKING THE MOLICULE IN THE TARGET PROTEIN  
OPTIMIZATION OF THE HIGHLY INTERACTING 
MOLECULE   
TOP SCORE COMPOUND SELECTED 
INSILICO INVESTIGATION OF DRUG LIKENESS 
AND TOXICOLOGICAL ASSESSMENT  
SYNTHESIS 
CHARACTERIZATI
ON – 
SPECTROSCOPY 
(IR,NMR,MASS) 
 IN-VITRO ANTI-TUBERCULAR ACTIVITY 
BY MABA 
AIM AND OBJECTIVES 
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PLAN OF WORK 
 
 The main aim of this project is to synthesize a novel compounds containing anti-
tubercular activity but my plan of work is over a 1000 molecules, a desired anti-
tubercular activity containing molecule is selected and an enzyme which is active 
against tubercular cells. 
 
 The selected enzyme is docking against compounds which is to be synthesized, in this 
docking score; drug interaction; binding action is important 
 
 The selected compounds were synthesized at appropriate manner then purified by 
recrystallization, characterized by sharp melting point, TLC. 
 
 The following compounds are confirmed by characterized techniques which is 
hyphenated like, GC-MS  and  LC-MS analysis(if necessary).In this technique, 
molecular weight and purity of the formed compounds are determined 
 
 The molecular structure of the compounds are interpretate by proton NMR (1HNMR) 
and the functional groups of the compounds are analyzed by IR studies 
 
 The anti-tubercular activity of the compounds are evaluated by MABA 
 
 The toxicity of synthesized compounds are visualized by OSIRIS 
 
Finally, a novel and potent anti-tubercular activity containing compounds are synthesized, 
purified, characterized and evaluated 
                                                                                 REVIEW OF LITERATURE 
 
Dept. of Pharmaceutical Chemistry, COP, MMC Page 29 
 
 
                                                REVIEW OF LITERATURE 
 
 
  On the basis of the designed process, thiophene have been identified as potential Anti-
tubercular molecules. It was therefore decided to conduct a literature survey of thiophene 
moieties and of the target glutamine synthetase 
 
1.Reviews related to the target- Glutamine synthase  
 
Marcus A. horwitz et al.,
[39]
 assessed the role of glutamine synthetase (GS), in the pathogenicity 
of mycobacterium tuberculosis; glnA1 was constructed via allelic exchange. The mutant had no 
detectable GS protein or GS activity and was auxotrophic for L-glutamine. In addition, the 
mutant was attenuated for intracellular growth in human THP-1 macrophages. Based on growth 
rates of the mutant in the presence of various concentrations of L-glutamine the importance of 
the enzyme was known. These studies demonstrate that glnA1 is essential for M.tuberculosis 
virulence.  
 
Berlicki L; kafarski 
[40]
 studied about the Glutamine synthases enzyme which catalyses the 
formation of glutamine from glutamine and ammonium ion. It is one of the most important 
enzymes in nitrogen metabolism. The first part of the review presents the long-dating research on 
inhibitors of glutamine synthetase. Analysis of their structure activity relationship is presented in 
some detail. The second part of the paper is dedicated to potential medical applications of 
glutamine synthetase inhibitors, which is proved as effective anti-tuberculosis agent with high 
selectivity towards the pathogen. 
  
Oolf Lagerlund
[41]
 synthesized some potential anti-tubercular agents which targeted Glutamine 
Synthetase (GS), is one of the latest targets of M.tb which catalyses the formation of glutamine 
from glutamic acid. In this work, novel GS inhibitors and new Pd (0) - catalyzed methods have 
been developed.  
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Wojciech W. krajewski et al.,
[42]
 summarized that glutamine synthetase catalyzes the ligation of 
glutamate and ammonia to form glutamine, with the hydrolysis of ATP. The enzyme is a central 
component of bacterial nitrogen metabolism and is a potential drug target. This study provides 
the first reported structure for a tauto form of the tuberculosis enzyme.  
The phospho compound, generated in situ by an active enzyme, mimics the phosphorylated 
tetrahedral adduct at the transition state. Some differences in ligand interactions of the protein 
with phosphorylated compound and nucleotide are observed compared with the earlier 
structures; a third metal ion also is found.  
 
B) Of the several works of thiophene, few of them are enlisted here in support of their 
thiophene antitubercular activity 
 
Shailesh J. Vaghasiya.et.al 
[43]
 evaluated synthesis, biological screening of novel pyrozolo 
(3’,4’;4,5) thieno (2,3-d) pyrimidin-8-ones, it was involved in a new synthetic route is proposed 
for the synthesis of 3,6-dimethyl-6-aryl- 1,5,6,7-tetra hydro-8H-pyrozolo(3’,4’:4,5)thieno (2,3-d) 
pyrimidin 8-one from 5-amino-3-methyl-1H-thieno(3,2c)pyrozole 6-carbanonitrile. The 
compounds (3a-h) were initially screened against Mycobacterium tuberculosis H
37 
RV (ATCC 
27294) (American Type Culture Collection, Manassas, Va.) at the single concentration of 6.25 
μg/ml in BACTEC 12B medium using a broth micro dilution assay, the microplate Alamar blue 
assay (MABA) 
 
                                  
S
NH
N
H
N
H
N
CH3
R
CH3
O
R – Phenyl; 2-OH phenyl 
                                                                                3a-h 
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Li-Hsun chen et.al:
[44]
  described utilizing 2-cyano methyl benzimidazole in a modified Gewald 
multicomponent reaction. The synthesis strategy involved treatment of 2(cyanomethyl)-
benzimidazole with aldehydes containing an active methylene group and sulfur powder under 
refluxing conditions. achieved a multicomponent condensation reaction on an  ionic liquid 
support to afford the benzimidazole linked thiophene.  
                                            
N
H
N
S
NH2
R2
R1
O
O
OH
 
 
C.Oliver kappe:
[45]
 reported that synthesized some novel  thiophene derivatives by microwave 
assisted methods, using gewald reaction it has been described anti-microbial activity; anti-
tubercular activity 
Ransborg.L.K.et.al
[46]
: revealed that the synthesis and anti-mycobacterial evaluation of some 
optically active thiophenes via an organometallic one-pot methodology 
           
    Ar: 3,5-(CF3)2-C6H3
R1 O
S
EWG
NH
R2
R1
HX
N
H
Ar
Ar
TMSO
EWG
N
S
R3
R2
Ar
 
 
                                                                                 REVIEW OF LITERATURE 
 
Dept. of Pharmaceutical Chemistry, COP, MMC Page 32 
 
 
Dong Cai 2015
[47]
: The compounds were evaluated for their preliminary in vitro antibacterial 
activity against some Gram-positive and Gram-negative bacteria and screened for antitubercular 
activity against Mycobacterium tuberculosis by the broth dilution assay method. Some 
compounds showed good antibacterial and antitubercular activities. The structures of the target 
compounds were confirmed by IR, 1H-NMR, 13C-NMR and HRMS studies. 
 
                                            
NH
N
+
N
S
O
R1
 
 
                                                     
Kan Wang.et.al
[48]
:  describe valuable general protocols for the synthesis of arrays of 2- 
aminothiophene-3-carboxamides from cyanoacetamides, aldehydes or ketones and sulfur via a 
Gewald-3CR variation. In many cases the reactions involve a very convenient work up by 
simple 
Precipitation in water and filtration. >40 new products are described.  
 
S
NH2
NH O  
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Nitinkumar S. Shetty (2014)
[49]
: In this journal, said that a facile microwave-assisted synthesis 
of novel thienopyrimidines and triazolothienopyrimidines and their anti-microbial activities. 
The following compounds showed promising anti-bacterial  activity and anti-fungal activity. 
Biological screening of these compounds shows mycobacterial activity; those activity was 62% 
of that of ampicillin against B. subtilis. 
                    O
CH3
CH3
S
N
N
H2NHN
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N
N
N
N
O
CH3
CH3
R
 
 
Vedia Ertuzun (1986
[50]
): studies described substituted heteroaromatic amines were 
synthesized by a cyclization reaction achieved by means a special base catalysed cyclization 
reaction, using alpha-hydroxy ketone and active methylene compounds. The purpose of this 
study was to synthesize substituted 2-amino-furane by placing furyl groups to the 4- and 5-
positions of the substituted heteroaromatic ring, using a special Knoevenagel condensation 
reaction; The pKa value of the compound was determined as 18.0, this reveals that furyl groups 
have much more electron withdrawing effect than phenyl groups.  
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Amir R. Jalilian.et.al (2008)
[51]
: This study shows a review of preparation and evaluation of 
isotopic thiophene-2-aldehyde thiosemicarbazide PET studies. Total labelling and formulation 
of [61Cu]TATS took about 40minutes, with a yield of more than 90%. A significant specific 
activity (9.1 TBq/mmol or 246 Ci/mmol) was formed via insertion of 61Cu cations. 
                                             
 
AshrafY.khan.et.al
[52]
: reported that the synthesis, characterization and biological evaluation of 
novel thienopyrimidine and triazolotheinopyrimidine derivatives as anti-tubercular and anti-
bacterial agents by gewald reaction. Most of these compounds exhibited MIC values in the 
range of 20 – 100 μM against Mycobacterium tuberculosis H37Rv. In the series, compound 5c 
was most active with MIC 20 μM. Some of these compounds exhibited MIC values in the range 
8 - 64μM. Compound 5c was found to be the most active with an MIC of 5 and 8μM 
respectively. 
 
                                        S
N
N
N N
R1
R
CH3
5a-c, R=CH3, R1=H, CH3, CH2CH3 
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Lianpao Wu
[53]
: it evaluated a high throughput screening of 17,500 compounds, two hit 
compounds containing a tetrahydrobenzothiophene core were identified as interesting biofilm 
inhibitors of Escherichia Coli UTI89. Thirteen compounds have been successfully synthesized 
from methyl 2-amino-6-phenyl-4, 5, 6, 7-tetrahydrobenzo[b] thiophene-3-carboxylate, which 
was prepared from Gewald three-component reaction. 
 
  
S
OCH3
O
Ph
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N
+
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+
OH
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OCH3
O
Ph
NH
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CH3
OH
O
R1  
 
                
Farid Moeinpour.et.al(2011):
[54]
 It describes that Cesium Carbonate as a Heterogeneous Base 
Catalyst for Synthesis of 2-Aminothiophenes via Gewald Reaction. The synthesis of substituted 
2-aminothiophenes is attractive to chemical researchers as they are important intermediates in 
organic synthesis and frequently used as the scaffold motif of a variety of agrochemicals, dyes, 
and biologically active products. 
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Chengyuan Liang.et.al (2014):
[55]
 It reveals that to describe Ultrasound-promoted synthesis of 
2-aminothiophenes accelerated by DABCO utilizing PEG-200 as solvent. An expeditious and 
greener one-pot procedure was developed for the synthesis of multisubstituted 2-
aminothiophene derivatives. In the presence of catalytic amount of DABCO, ketones or 
aldehydes, dicyanomethane and elemental sulfur were converted into the corresponding 2-
aminothiophene derivatives in moderate to high yields in PEG-200 under sonication. 
 
 
                             
R1
R2
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Zita Puterova.et.al(2009):
[56]
  It involved in application of substituted 2-amino thiophene in 
drug design. Highly substituted thiophene derivatives are important heterocycles found in 
numerous biologically active compounds. 
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William C. Shearouse (2014):
[57]
 This studies show a solvent-free, one-step, one-pot gewald 
reaction for alkyl-aryl ketones via mechanochemistry, the Gewald reaction can be catalytic in 
base, and conducted under aerobic conditions. Using thermal heat in tandem with the mixer/mill 
significantly increases the rate of reaction. 
 
        
N
OEt
O
+
O2N
O
CH3 S8
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HSBC1/8 SS Ball
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Stanislav Radl (2005):
[58]
 it involved in the modification of the Gewald methodology for the 
synthesis of 3-amino-2-(1H-1,2,3-benzotriazol-1-yl) substituted benzofurans, benzothiophenes 
and 1H-indoles. The synthesized compound shows promising anti-bacterial activity which was 
evaluated by MABA. 
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Gewald thiophene synthesis with siloxycylopropanes (1961) 
[59]
: It involved in the synthesis 
of polysubstituted thiophenes from the multicomponent condensation of ketones or aldehydes, 
activated nitriles and elemental sulfur was originally published in 1961 by Gewald and co-
workers.  
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Castanedo.G.M:
[60]
 This studies reveals that the synthesis of tetra substituted thiophene on 
solid-support using the Gewald reaction. This reaction combines a ketone or aldehyde, an 
activated nitrile,and sulfur in the presence of a suitable amine base to make tri and tetra 
substituted thiophenes. After optimizing conditions for maximum yield and purity, the scope of 
the reaction was investigated. Finally this method is highlight in the synthesis of two 
biologically relevant compounds 
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Sridhar.M.et.al:
[61]
 In this study, reaction assisted by microwave accelerated Gewald reaction 
involved in the synthesis of 2-aminothiophene by multicomponent reaction of a ketone with an 
active nitrile and elemental sulfur under KF-alumina catalysis is described 
 
                              
 
Hallas. G[62]  it states that, dyes derived from aminothiophene involved in the synthesis of some 
heterocyclic disperse dyes using the Gewald reaction. A series of red to violet thienyl-2-azo disperse 
dyes has been derived from aminothiophenes synthesised directly by using the Gewald reaction. 13C 
NMR data for certain derivatives are reported. 
 
Synthetic communications (International Journal)
[63]
: describes organic reactions in ionic 
liquids, Gewald synthesis of 2-aminothiophenes catalyzed by Ethylenediammonium Diacetate. 
Ionic liquids based on 1‐butyl‐3‐methylimidazolium tetrafluoroborate (BmimBF4) and 1‐butyl‐
3‐methylimidazolium hexafluorophosphate (BmimPF6) were used as reusable alternatives to 
volatile organic solvents (VOCs) for ethylenediammonium diacetate (EDDA) catalyzed Gewald 
synthesis of 2‐aminothiophenes. Significant rate enhancement and improvement of the yield 
were observed. The ionic liquids containing catalyst EDDA were recycled several times with no 
decreases in yields and reaction rates. 
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REVIEW RELATED TO THIOPHENE NUCLEUS AND ITS BIOLOGICAL 
ACTIVITIES 
Mishra.R
[64]
: It involved in review of synthesis, properties and biological activity of thiophene 
nucleus has been established as the potential entity in the largely growing chemical world of 
heterocyclic compounds possessing promising pharmacological characteristics. The recent 
review provides a broad view of the synthesis and properties of compounds having thiophene 
nucleus. 
Well known major synthetic procedure includes: paal-knorr thiophene synthesis, fiesselmann 
thiophene synthesis, Gewald aminothiophene synthesis and hinsberg synthesis.  
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Rajeev kharb
[65]
: reported that to design and synthesize novel antimicrobial agents to solve the 
problem of microbial resistance towards conventional antimicrobial agents. Among the various 
types of heterocyclic compounds, benzothiophene plays an important role in the medicinal 
chemistry because it possesses promising antibacterial, antifungal and antitubercular activities. 
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This articles aims to review antimicrobial activities of novel benzothiophene derivatives during 
recent years which reveal their biological potential as anti-infective agents. 
 
 
Bhatt.R.et.al:
[66]
 studies reveals that the synthesis, characterization and anti-microbial 
evaluation of some tetrahydroquinazoline derivatives of benzothiophenes.  
The structures of the newly synthesized compounds were elucidated on the basis of IR and 1H NMR 
spectral data of the compounds. 
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Abdou.M.M.et.al
[67]
: thiophene nucleus may also be used in the field of dyes chemistry. A 
series of red to blue hetarylazo dyes 15 with good fastness was synthesized by coupling reaction  
of 4-aryl-2-aminothiophenes derivatives with diazotized 5-nitro-2-aminothiazole and 6-nitro-2-
aminobenzothiazole, respectively, as diazo components.  
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Mittal.M.et.al:
[68]
 synthesis, characterization and anti-microbial activity of substituted tricyclic 
compounds, it may be 5,6,7,8-tetrahydro pyrido[4’,3’:4,5]thieno[2,3-D] pyrimidines using 
piperidin-4-one Hydrochloride and benzenesulfonyl chloride asthe starting material. All the 
synthesized products were evaluated for their antibacterial activity. The structures of all the 
synthesized compounds have been determined by their spectral and microanalytical data. 
 
                       
S
N
S
N
N
O
O
R1
NH
R2
R3
 
  
 
Kallepalli.V.A.et.al:
[69]
 it is a divergent synthesis; which involved in the synthesis of 2,3,5-
substituted thiophenes by C-H activation/borylation/Suzuki coupling. 
2 Thiophenes are an important class of heterocyclic compounds with applications in the design 
of advanced materials to the treatment of various diseases. 
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S
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Sidhu.P.S.et.al(2014):
[70]
 it is a computational studies that involved in the QSAR study of 
thiophene-anthranilamides based factor Xa direct inhibitors.  
 
QSAR studies were performed to understand the structure activity relationship (SAR) 
and to build the computational model to predict newer inhibitors with improved potency. In this 
study, a library of thiophene-anthranilamide based inhibitors of factor Xa was used to develop 
QSAR model. The library was divided into two sets: Training and Test sets. QSAR Model 
consists of four descriptors with R-square value of 0.80. Based on the statistical parameters, this 
model can be used to predict the newer inhibitors with improved pharmacological profile. 
 
 
Verma.A.K.et.al:
[71]
 it involved in the synthesis, characterization and screened for anti-
mycobacterial activity of novel N-(sugar pyranosyl) thienopyrimidine 4-amine derivatives. 
These derivatives were identified on the basis of melting point range, Rf values, IR and 1H 
NMR spectral analysis. The derivatives exhibited significant to promising antimicrobial activity 
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Chaudhary.A.et.al (2012)
[72]
: describes biological diversity of thiophene, it explained about 
review of thiophene. Thiophene has been established as the potential entity in the largely 
growing chemical world of heterocyclic compounds possessing promising pharmacological 
characteristics. This review provides various synthetic strategies of thiophene analogues. The 
following compounds provides promising anti-microbial activity.  
 
                   
S
R1
R
N
SNH
N
N
O
NH
N
S
N
N
O
R1
R = NHCOCH3  
 
                   
Deligeorgiev.T.et.al (2011)
[73]
:  concluded an environmentally benign synthesis of 2-
cyanomethyl-4-phenylthiazoles under focused microwave irradiation. The methods allows the 
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synthesis of products in excellent yields with short times and the work-up is easy. This approach 
can be applied to the preparation of a variety of derivatives. 
  
S
N
CH2CN 
 
 
 
 
 
Kachhadia.V.V.et.al (2004):
[74]
 described synthesis of isoxazoles and cyanopyridines bearing 
benzothiophenes nucleus as potential anti-tubercular and anti-microbial agents. The reaction 
was carried out by condensing chalcones with hydroxylamine hydrochloride and malononitrile. 
All the synthesized compounds were established on the basis of elemental analyses IR, 1H 
NMR and Mass spectral data and screened for their anti-tubercular and anti-microbial activities. 
 
                                             
S
CONH
N
O
R
Cl
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Mancuso.R.et.al (2014):
[75]
 described review of recent advances in the synthesis of thiophene 
derivatives by cyclization of fuctionalized alkynes. 
 
              
                             S
Co2EtPh
OMe
S
CO2Me
Me2N
CO2Me
Co2Et
O
 
  
 
 
 
 
 
Y. Li, J. Wang.et.al (2014):
[76]
 described low catalyst loading of a bis(alkoxo)palladium 
complex enables an efficient phosphine-free direct C-H arylation of thiophenes at C2. The 
developed synthetic method couples aryl or heteroaryl bromides with thiophenes bearing 
electron-donating or electron-withdrawing groups and other heterocyclic moieties such as 
benzothiophenes.  
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B. Gabriele.et.al:
[77]
 Various readily available 1-mercapto-3-yn-2-ols 5 were conveniently 
converted into the corresponding thiophenes in good to high yields in MeOH as solvent in the 
presence of PdI2 as catalyst and KI as additive. The use of BmimBF4 as solvent enables the  
recycling of the catalyst. 
 
 
 
          
 
 
 
 
 
 
G. Zhang.et.al:
[78]
 The interaction between elemental sulfur and NaOtBu enables a facile 
single-step protocol for the synthesis of thiophene derivatives from 1,3-diynes. A plausible 
mechanism based on EPR experiments revealed that the trisulfur radical anion acts as a key 
intermediate of this process. 
 
           
                 
    
 
S. Tamba.et.al:
[79]
 A palladium-catalyzed C-H arylation of electron-enriched heteroarenes with 
aryl bromides and aryl chlorides proceeds in the presence of LiO-t-Bu as a base.  
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O. Bayh.et.al:
[80]
 Thiophene was regioselectively deprotonated by treatment with Bu3MgLi in 
THF at room temperature. The lithium arylmagnesate formed was either trapped with 
electrophiles or cross-coupled in a ‘one-pot’ procedure with aryl halides under palladium 
catalysis. 
 
            
       
 
 
 
4.Reviews related to biological evaluation of antitubercular activity by MABA  
 
Sephra N.Ramprasad 
[81]
 studied the various applications of Alamar blue as an indicator. 
Alamar blue is an indicator that is used to evaluated metabolic function and cellular health. The 
Alamar blue bioassay is being utilized to access cell viability and cytotoxicity in a biological and 
environmental system and in a number of cell types including bacteria, yeast, fungi, and 
protozoa. 
  
Jose d Jesus Alba-Romero et al 
[82]
 applied the Alamar blue assay to determine the 
susceptibility to anti-tuberculosis pharmaceuticals. The results showed that the MABA test is 
fast and easy to apply. It is very reliable method to determining the drug susceptibility to 
pharmaceuticals.  
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                                             MATERIALS AND METHODS 
 
 
DRUG DESIGN 
    
                A binding interaction between a small molecule ligand and an enzyme protein 
results in activation or inhibition of the enzyme which results in agonism or antagonism. 
 
GLIDE DOCKING 
 
                  Glide is one of the docking programs which predicts the binding mode of ligand 
to a protein (target). It ranks the ligands via high-throughput virtual screening. Extra 
prediction mode (XP) was used to rank order the compounds based on the interaction with 
the receptors. 
 
 Protein preparation 
 
 Ligand preparation  
 
 Receptor grid generation 
 
Ligand docking (screening) 
 
MOLECULAR DOCKING BY ARGUS LAB SOFTWARE 
[37] 
         
             Docking of ligands is carried out by Argus lab docking software. Docking allows the 
medicinal chemist to virtually screen a set of compounds and predict the strongest binding 
capacity based on various scoring function. It explores ways in which two molecules such as 
ligand and receptor (protein) fit together and docks to each other well. The molecule binding to 
a receptor inhibits its function and thus acts as drug.  
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Argus lab 4.0 distributed freely for windows platforms by planaria software,  is an introductory 
molecular modeling package with academics. Argus docking engine implementry in Argus lab 
approximates an exhaustive search method which is similar to DOCK and GLIDE. Flexible 
ligand docking is possible with Argus lab, where the ligand is described as torsion tree and 
grids are constructed that overlay the binding site. The accuracy of the Argus lab docking 
algorithm takes into account, the key features such as the nature of the binding site and the 
number of rotatable bonds to the ligand.  
 
Molegro molecular viewer: Molegro molecular viewer is an application which helps in 
analyzing the energies and interaction of the binding site. 
           Q-site finder is an energy-based method for protein-ligand binding site prediction. During 
prediction we use the crystal structures of macromolecules (receptor) with small substrates (pdb 
ID). Identifying the location of binding sites on a protein is of fundamental importance for a 
range of applications including molecular docking. It uses the interaction energy between the 
protein and a simple vanderwaals probe to locate energetically favourable binding sites.  
 
A .PREPARATION OF PROTEIN 
 
STEP 1:  
 
 Enter protein pdb ID (4ACF) in the protein data bank.  
 
 Go to download files and select pdb as text file.  
 
 Save the downloaded pdb text file to desktop.  
 
STEP 2:  
 
 Open Argus lab file → open → Import pdb file from the desktop.  
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 3D structure of the protein will appear in the workspace of Argus lab.  
 
 Left side of the screen shows molecular tree view.  
 
 Open pdb → open ‘Residues’ → open ‘Misc’.  
 
 From ‘Misc’ delete the inhibitor and hetero residues, do not delete cofactor.  
 
 Open water press shift, select all water molecules and delete.  
 
 Add hydrogen atoms.  
 
 Go to calculation on toolbar → energy by UFF method → start.  
 
 Save the prepared protein as *.agl file format in the desktop. 
 
B.IDENTIFICATION/ SELECTION OF ACTIVE SITE  
 
STEP 1:  
 
 Open Q-site finder through online.  
 
 Upload/Import the pdb format of the protein.  
 
 Find all the active site and make a list out of the common amino acid residues.  
 
STEP 2:  
 
 Open residues → open amino acids  
 
 Press control and select the amino acids which were listed from the Q-site finder.  
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 Make sure that all the amino acid residues listed are selected.  
 
 Right click on the mouse → make a group from the selected residues → give name 
→ Binding site → OK.  
 
C.PREPARATION OF LIGANDS  
 
 Draw the structure from chem. Sketch and save as MDL mol format.  
 
 Import the ligand into workspace of Argus lab.  
 
 Clean geometry → clean hybridization.  
 
 Select the ligand, right click on the mouse → make a group from the residues → give 
name→ ligand→ OK.  
 
D.DOCKING PARAMETER  
 
 Select calculation from the toolbar → Dock a ligand 
 
 ‘Argus Dock’ as the Docking engine  
 
 ‘Dock’ was selected as calculation type  
 
 ‘Flexible’ for the ligand  
 
 Ascore as the scoring function  
 
 Calculation size  
 
 Start docking  
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 Save the Docked protein Ligand complex as Brookhaven pdb files (*.pdb)  
 
 
B.VISUALIZATION/INTERPRETATION OF DOCKING  
          
Molegro molecular viewer helps in analyzing the energies and interaction of the 
binding. 
[38] 
  
 
 
Lipinski’s rule 
 
          Lipinski’s rule of five is a rule of thumb to evaluate drug likeness, ie., or to determine 
if a chemical compound with a certain pharmacological or biological activity has the 
properties that would make it a likely orally active drug in humans. The rule was 
formulated by Christopher A. Lipinski in 1997, based on the observation that most 
medication drugs are relatively small and lipophilic molecules.  
           
The rule describes molecular properties important for a drug’s pharmacokinetics in the 
human body, including their absorption, distribution, metabolism and excretion (ADME). 
However, the rule does not predict if a compound is pharmacologically active.  
 
The rule is important for the drug development where a pharmacologically active lead 
structure is optimized step-wise for increased activity and selectivity, as well as drug-like 
properties as described by Lipinski’s rule. The modification of the molecular structure often 
leads to drugs with higher molecular weight, more rings, more rotatable bonds, and a higher 
lipophilicity. 
         
Lipinski’s rule says that, an orally active drug has no more than one violation of the 
following criteria: 
             
Not more than 5 hydrogen bond donors (nitrogen or oxygen atoms with one or more 
hydrogen atoms) 
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Not more than 10 hydrogen bond acceptors (nitrogen or oxygen atoms) 
 
Molecular weight under 500 daltons 
 
Partition coefficient of log P less than 5 
 
                                             
                                              HETEROCYCLIC CHEMISTRY 
 
      Heterocyclic structures always are a part in the field of research and development in organic 
chemistry. Millions of heterocyclic structures are found to exist having special properties and 
biological importance. Among various compounds, I have chosen thiophene a five membered ring 
containing sulfur moiety.  
 
THIOPHENE NUCLEUS 
                                                                       S  
 
The following synthetic reactions are involved for synthesizing thiophene containing compounds 
 
Paal Knorr Synthesis 
Hinsberg synthesis of thiophene 
Gewald Reaction  
 
SYNTHETIC METHODOLOGY 
 
         In this methodology, using Gewald synthetic process synthesizing novel compounds 
using different characterized alpha-methyl ketones, malononitrile and elemental sulfur, 
further  reaction carried out by using ethanol as a solvent. 
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SYNTHETIC PROCEDURE 
          
       In this synthetic procedure, 1
st
 step involved in alpha-methyl ketone like( meldrum’s 
acid and cycloheptanone), malonitrile is dissolved in ethanol (used as a solvent),  add 
diethylamine as a catalyst (half quantity of calculated amount) the reaction mixture stirred 
at room temperature for about 18hrs. Completion of the reaction is comfirmed by TLC and 
detected by UV chamber. 
 
        After completion of the reaction, in the reaction mixture remaining quantity of 
diethylamine and crushed elemental sulfur is added and reflux with stirring is carried out 
until sulfur completely dissolved and the temperature is maintained at 60 – 800C (over 5-
6hrs). Then the mixture again stirred at room temperature for 12 hrs. The completion of the 
reaction was confirmed by TLC and the reaction mixture poured into crushed ice. Finally 
the product was obtained which was recrystallized by using various organic solvents like 
ethanol, ethyl acetate, etc. 
 
             
                                          SYNTHETIC REACTIONS 
 
                                                                  
O
O
O
CH3
CH3
O
+ S8
Diethylamine
reflux at 60-70C
NC CN
O
O
S
CN
NH2
O
CH3
CH3
O
+ S8
S
CN
NH2
Diethylamine
reflux at 60-70C
CNNC
Meldrum's acid
Cycloheptanone
6-amino-2,2-dimethyl-4-oxo-4H-thieno[3,2-d][1,3]dioxine-7-carbonitrile
2-amino-5,6,7,8-tetrahydro-4H-cyclohepta[b]thiophene-3-carbonitrile
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REACTANT PROFILE                  
 
MELDRUM’S ACID 
STRUCTURE 
 
O
O
O
CH3
CH3
O
 
 
SYNONYM                                Meldrum’s acid 
 
MOLECULAR FORMULA      C6H8O4 
MOLECULAR WEIGHT         144.15 
SOLUBILITY                            Soluble in Ethanol, ethyl acetate, methanol 
DESCRIPTION                         Yellowish white salt (hygroscopic) 
MELTING POINT                      192-194
0
C 
 
 
MALONITRILE 
STRUCTURE 
CN
NC  
 
 
SYNONYM                             Malonitrile 
MOLECULAR FORMULA     C3H2N2 
SOLUBILITY                            Soluble in ethanol and sparingly soluble in ethyl acetate 
DESCRIPTION                          Liquid in nature ( reddish brown) 
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DIETHYLAMINE                 
SYNONYM                               Diethylamine 
MOLECULAR FORMULA      73.14 
SOLUBILITY                             Soluble in ethanol 
DESCRIPTION                           Colorless liquid 
 
 
SYNTHETIC DERIVATIVES 
 
The derivatives of the compounds were synthesized by following procedure 
 
6-AMINO-2,2-DIMETHYL-4-OXO-4H-THIENO(3,2-d)(1,3)DIOXINE-7-
CARBONITRILE                                                                                                                           
2-AMINO-5,6,7,8-TETRAHYDRO-4H-CYCLOHEPTA(b)THIOPHENE-3-
CARBONITRILE 
 
 
        The above synthesized compounds (intermediate) are again reacted with following 
acids like glacial acetic acid, formic acid and carbondisulphide. 
 
         In the compound A and B, add 20ml of formic acid and 3 drops of conc.H2 SO4, 
temperature is maintained at 80
0
C for 12hrs,  pyrimidine analogue is formed. 
 
         In the compound A and B,10ml of carbondisulphide and ethanolic potassium 
hydroxide as a solvent and the reaction is carried out reflux with stirring for 12hrs, 
temperature maintained at 80
0
C 
 
         In the compound A and B, add 30ml of glacial acetic acid (used as a solvent), and the 
temperature is maintained at 80
0
C for 12hrs 2 methyl pyrimidine analogue is formed. 
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REACTION: 
 
COMPOUND NAME: CMG 
 
 
 
               
S
NH2
CN
CH3COOH
H2O
S
N
N
H
CH3
O
 
 
2-amino-5,6,7,8-tetrahydro-4H- 
cyclohepta[b]thiophene-3-carbonitrile                2-methyl-4a,5,6,7,8,9-hexahydro-4H-                                       
                                                                           cyclohepta[4,5]thieno[2,3-d]pyrimidi 
 
 
MECHANISM 
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COMPOUND NAME: MMG 
 
            
O
O
S
O
CH3
CH3
NH2
CN
CH3COOH
H2O
O
O
S
N
H
N
O
CH3
CH3
CH3
O
 
 
           6-amino-2,2-dimethyl-4-oxo-4H-thieno                              
            [3,2-d][1,3]dioxine-7-carbonitrile 
                                                                                             2,2,7-trimethyl-9,9a-dihydro-4H-[1,3] 
                                                                          dioxino[4',5':4,5]thieno[2,3-d]pyrimidin-4-one  
                                                                                
MECHANISM 
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COMPOUND NAME: MC 
 
 
        
O
O
S
O
CH3
CH3
NH2
CN
CS2
Ethanolic KOH
O
O
S
N
H
NH
O
CH3
CH3
NH
S
 
 
6-amino-2,2-dimethyl-4-oxo-4H-thieno 
[3,2-d][1,3]dioxine-7-carbonitrile                              9-imino-2,2-dimethyl-7-thioxo-6,9-
dihydro- 
                                                                                 4H,7H-[1,3]dioxino[4',5':4,5]thieno[2,3-                             
                                                                                         d][1,3]thiazin-4-one  
 
        MECHANISM                                                                                                
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COMPOUND NAME: CC 
 
 
      
S
NH2
CN
S
NH
N
H
S
S
CS2/ KOH
 
 
 
 
2-amino-5,6,7,8-tetrahydro-4H- 
cyclohepta[b]thiophene-3-carbonitrile                    4-imino-1,5,6,7,8,9-hexahydro-2H,4H- 
                                                                   cyclohepta[4,5]thieno[2,3-d][1,3]thiazine-2-thione 
 
 
MECHANISM 
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COMPOUND NAME: MMF 
 
             
O
O
S
O
CH3
CH3 NH2
CN
HCOOH
O
O
S
O
CH3
CH3
N
H
N
O
 
 
6-amino-2,2-dimethyl-4-oxo-4H-thieno 
[3,2-d][1,3]dioxine-7-carbonitrile                           2,2-dimethyl-9,9a-dihydro-4H-[1,3] 
                                                                          dioxino[4',5':4,5]thieno[2,3-d]pyrimidin-4-one  
 
 
METHODS OF IDENTIFICATION 
 
             The synthesized compounds were identified by using following methods. 
 
Melting point 
              The melting point of the compounds are determined by the capillary tube method. 
The synthesized compounds were start losing their crystallinity at a particular temperature. 
 
Thin layer chromatography 
 
              Pre-coated TLC plates with silicagel GF 250 are used. Samples of reactants and 
products are prepared with suitable solvents. 
The characterization was carried out using sophisticated methods like Infra-red 
spectroscopy, Nuclear magnetic resonance spectroscopy and Mass spectroscopy. 
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INFRA RED ABSORPTION SPECTROSCOPY 
 
               IR (region 2.5-15) is a powerful tool for identifying pure organic and inorganic 
compounds because. With the exception of a few homo nuclear molecules such as O2, N2, 
Cl2 all the molecular species absorb infrared radiation. With the exception of chiral 
molecules in the crystalline state, each molecular species has a unique infrared absorption 
spectrum. 
 
NMR SPECTRA 
 
               Nuclear magnetic resonance involves the interaction between oscillating magnetic 
field of electromagnetic radiation and the magnetic energy of the hydrogen nucleus or some 
other type of nuclei when these are placed in an external static magnetic field. 
NMR spectroscopy in which radiofrequency waves induces transitions between magnetic 
energy levels of nuclei of a molecule. NMR enables us to study the number of equivalent 
protons and their electronic environment. It reveals the different chemical environment in 
which the proton is present and helps us to ascertain the structure of molecule 
The number of signals in an NMR spectrum denotes the number of the set of equivalent 
protons in a molecule. The position of the signals in the spectrum helps us to know the 
nature of protons such as aromatic, aliphatic, acetylenic, vinyl, adjacent to some electron 
attracting or electron releasing group etc. the splitting of the signal is due to the different 
environment of the absorbing proton with respect to the adjacent protons and not with 
respect to electrons. 
 
MASS SPECTROSCOPY 
 
               Mass spectroscopy is an analytical techniques used to establish the molecular 
structure and the molecular weight of the analyte under investigation. In this technique, the 
compound under investigation is bombarded with a beam of electrons producing ionic 
fragments of the original species. The relative abundance of the fragment ion formed 
depends on the stability of the ion and of the lost radical. The resulting charged particles are  
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 then separated according to their masses. Mass spectrum is a record of information 
regarding various masses produced and their relative abundances. 
 
 
BIOLOGICAL SCREENING FOR ANTI-TB ACTIVITY 
 
       This screening is for the compounds that have the potential to be developed in to new drugs 
against tuberculosis because the compounds inhibit the enzymes required for the formation of cell 
wall of the tuberculosis bacterium. New drugs are needed in current date, because the rates of cure 
with present drugs are very slow, and prevalence of mycobacterium tuberculosis resistance to the 
present drugs is increasing. 
  
ANTITUBERCULAR ACTIVITY 
 
The following methods have been used for invitro studies for the evaluation of anti-
tubercular activity. 
 
 Resazurin Micro plate Assay (REMA) 
 Nitrate Reductase Assay (NRA) 
 Micro plate Alamar Blue Assay (MABA) 
 3-(4,5 dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) 
 Middle Brook 7H11 Agar dilution Assay 
 Broth Micro dilution Method 
 BACTEC system 
 Luciferase Reporter Phage Assay 
 
The synthesized compounds may be evaluated for anti-tubercular activity using any of the 
above methods. In this techniques, Microplate Alamar Blue Assay is used to evaluate the 
anti-tubercular activity.                             
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MICROPLATE ALAMAR BLUE ASSAY 
 
Alamar blue dye is used as an indicator for the determination of viable cells. 
The oxidized form, Resazurine (also called as diazo-resorcinol, azoresorcin, resazoin and resazurine) 
is non- toxic, non-fluorescent and blue in colour which becomes pink and fluorescent upon reduction 
to resorufin by viable cells. 
Growth is measured qualitatively by a visual colour change and the amount of fluorescence produced 
is proportional to the number of the living cells which is determined by colorimetric and fluorimetric 
methods. 
 
Advantages 
 Easy to use 
 High sensitivity 
 Does not require cell lysis 
 Works well with different types of cells 
 Safe and economical 
 Inexpensive 
 Results are linear and quantitative  
 
ASSAY PROCEDURE FOR ESTIMATING ANTI-TB ACTIVITY USING 
Alamar Blue DYE  
 
 The anti-mycobacterial activity of compounds is assessed against M. tuberculosis  
using Alamar Blue micro plate assay (MABA). 
 This methodology is non-toxic, uses a thermally stable reagent and shows good 
correlation with proportional and BACTEC radiometric method. 
 Briefly, 200 micro litter of sterile de-ionized water is added to all outer perimeter 
wells of sterile 96 wells plate to minimize evaporation of medium in the test wells during 
incubation. 
                                                                       MATERIALS AND METHODS 
 
Dept. of Pharmaceutical Chemistry, COP, MMC Page 66 
 
 
 The 96 wells plate receive 100 micro litter of the middle brook 7H9 broth and serial 
dilution of compounds are made directly on plate. 
 The final drug concentrations tested are 100 to 0.2 micro gram/ml. 
 Plates are covered and sealed with paraffin and incubated at 37C for five days. 
 After this time, 25 micro litters of freshly prepared 1:1 mixture of Alamar blue 
reagent and 10% tween 80 is added to the plate and incubated for 24 hrs. 
 A blue colour in the well is interpreted as no bacterial growth, and pink colour was 
scored as growth. 
 The MIC is defined as lowest drug concentration which prevents the colour change 
from blue to pink. 
 
IN SILICO TOXICITY PREDICTION  
 
       In silico toxicity prediction is done using OSIRIS Property Explorer. It is free software available for 
access in the Organic Chemistry Portal. Using this prediction tool, mutagenicity, tumerogenicity, skin 
irritation and reproductive effects can be calculated. The prediction properties relies on a precompiled set 
of structure fragment that gives rises to toxicity alerts in case they are encountered in the structure 
currently drawn. These fragment lists is created by rigorously shredding all compounds in the data base 
known to be active in a certain toxicity class. During the shredding any molecule is first cut at every 
rotatable bonds leading to a set of core fragments.  
The designed and docked molecules are screened in silico using MOLINSPIRATION 
Cheminformatics software to evaluate drug likeness. This tool is quick and easy to use. It is a software 
available online for calculation of important molecular properties 9logP, polar surface area, number of 
hydrogen bond donors and acceptors and others, as well as prediction of bioavailability score for the most 
important drug targets(GPCR ligands, Kinase inhibitors, ion channel modulators, nuclear receptors) 
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RESULTS AND DISSCUSSION 
 
Dept. of Pharmaceutical Chemistry, COP, MMC Page 67 
 
 
RESULTS AND DISSCUSSION 
 
Nearly 200 molecules were sketched using chem sketch, and the molecules which is 
novel to be docked against the enzyme using Argus Lab 4.0.1 software. 
The following molecules were docked against different targets and the molecules with best 
docking score and good interaction were selected and synthesis. 
 
Molecules docked against different targets; 
 
1. Glutamine Synthetase I 
2. Methoxy Mycolic acid Synthase II 
3. Cyclopropane Mycolic Acid Synthase II 
4. L,D-Transpeptidase 
5. Decaprenyl Phosphoryl-b-d-Ribose2’-EpimeraseI (DprEI) 
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         TABLE NO 1: DOCKING SCORE OF THE SYNTHESIZED COMPOUNDS  
NAME OF THE 
ENZYMES 
 
DOCKING SCORES(Kcals/mol) 
   CMG   MMG    MMF      MC     CC 
  
GLUTAMINE 
SYNTHETASE I 
METHOXY 
MYCOLIC ACID 
SYNTHASE I 
CYCLOPROPANE 
MYCOLIC ACID 
SYNTHASE 
L,D-
TRANSPEPTIDASE 
        DprEI 
 
-7.4572 
 
-8.8865 
 
-7.3218 
 
-6.7842 
 
-7.8352 
 
-7.4632 
 
-9.6543 
 
-7.3490 
 
-7.2143 
 
-6.9874 
 
-7.8345 
 
-7.9854 
 
-8.6721 
 
-6.9543 
 
-7.5632 
 
-7.5543 
 
-8.7651 
 
-7.7423 
 
-6.8974 
 
-7.8974 
 
-9.3876 
 
-9.7641 
 
-9.9732 
 
-7.7542 
 
-7.5417 
    
INTERACTION OF THE DOCKED MOLECULES WITH THE ENZYME 
GLUTAMINE SYNTHETASE 
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TABLE NO 2: DOCKING VIEW AND THEIR INTERACTION    
SAMPL
E CODE 
DOCKING VIEW INTERACTION WITH AMINOACIDS 
CM                                                                                             
  
MM       
 
     
   
CMG  
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MMG 
  
MMF 
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MC 
 
 
CC 
 
  
 
RESULTS OF SCHEMES 
Physicochemical properties of 2-methyl-4a,5,6,7,8,9-hexahydro-4cyclohepta[4,5]thieno[2,3-
d]pyrimidine   Compound name: CMG 
 
Molecular Formula   = C12 H16 N2 S 
 
Formula Weight  = 220.335 
 
Composition              = C(65.41%) H(7.32%) N(12.71%) S(14.55%) 
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Molar Refractivity  = 63.93 ± 0.5 cm
3 
 
Molar Volume  = 163.2 ± 7.0 cm
3 
 
Parachor              = 434.7 ± 8.0 cm
3 
 
Index of Refraction  = 1.711 ± 0.05 
 
Surface Tension  = 50.2 ± 7.0 dyne/cm 
 
Density              = 1.34 ± 0.1 g/cm
3 
 
Dielectric Constant  = Not available 
 
Polarizability     = 25.34 ± 0.5 10
-24
cm
3 
 
Monoisotopic Mass  = 220.103419 Da 
 
Nominal Mass  = 220 Da 
Average Mass    = 220.337893 Da  
 
 
Physicochemical properties of 2,2,7-trimethyl-9,9a-dihydro[1,3]dioxino[4',5':4,5]thieno[2,3-
d]pyrimidin-4-one  Compound name: MMG 
 
Molecular Formula  = C11 H12 N2 O3 S 
 
Formula Weight  = 252.291 
 
Composition              = C(52.37%) H(4.79%) N(11.10%) O(19.02%) S(12.71%) 
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Molar Refractivity  = 63.11 ± 0.5 cm
3 
 
Molar Volume  = 161.1 ± 7.0 cm
3 
 
Parachor              = 440.0 ± 8.0 cm
3 
 
Index of Refraction  = 1.712 ± 0.05 
 
Surface Tension  = 55.6 ± 7.0 dyne/cm 
 
Density              = 1.56 ± 0.1 g/cm
3 
 
Dielectric Constant  = Not available 
 
Polarizability     = 25.02 ± 0.5 10
-24
cm
3 
 
Monoisotopic Mass  = 252.056864 Da 
 
Nominal Mass  = 252 Da 
 
Average Mass             = 252.292867 Da 
 
Physicochemical properties of 2,2-dimethyl-9,9a-dihydro-4[1,3]dioxino[4',5':4,5]thieno[2,3-
d]pyrimidin-4-one  Compound name: MMF 
 
Molecular Formula  = C10 H10 N2 O3 S 
 
Formula Weight  = 238.264 
 
Composition     = C(50.41%) H(4.23%) N(11.76%) O(20.14%) S(13.46%) 
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Molar Refractivity  = 58.69 ± 0.5 cm
3 
 
Molar Volume  = 145.9 ± 7.0 cm
3 
 
Parachor              = 408.9 ± 8.0 cm
3 
 
Index of Refraction  = 1.737 ± 0.05 
 
Surface Tension  = 61.7 ± 7.0 dyne/cm 
 
Density              = 1.63 ± 0.1 g/cm
3 
 
Dielectric Constant  = Not available 
 
Polarizability     = 23.26 ± 0.5 10
-24
cm
3 
 
Monoisotopic Mass  = 238.041214 Da 
 
Nominal Mass  = 238 Da 
 
Average Mass   = 238.265878 Da 
 
Physicochemical properties of 9-imino-2,2-dimethyl-7-thioxo-6,9-dihydro-4H,7H-
[1,3]dioxino[4',5':4,5]thieno[2,3-d][1,3]thiazin-4-one  Compound name: MC 
 
Molecular Formula  = C10 H8 N2 O3 S3 
 
Formula Weight  = 300.380 
 
Composition              = C(39.98%) H(2.68%) N(9.33%) O(15.98%) S(32.03%) 
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Molar Refractivity  = 72.68 ± 0.5 cm
3 
 
Molar Volume  = 161.2 ± 7.0 cm
3 
 
Parachor              = 474.6 ± 8.0 cm
3 
 
Index of Refraction  = 1.861 ± 0.05 
 
Surface Tension  = 75.1 ± 7.0 dyne/cm 
 
Density              = 1.86 ± 0.1 g/cm
3 
 
Dielectric Constant  = Not available 
 
Polarizability    = 28.81 ± 0.5 10
-24
cm
3 
 
Monoisotopic Mass  = 299.969706 Da 
 
Nominal Mass  = 300 Da 
 
Average Mass             = 300.378703 Da 
 
 
Physicochemical properties of 4-imino-1,5,6,7,8,9-hexahydro-2H,cyclohepta[4,5]thieno[2,3-
d][1,3]thiazine-2-thione  Compound name: CC 
 
Molecular Formula  = C11 H12 N2 S3 
 
Formula Weight  = 268.424 
 
Composition              = C(49.22%) H(4.51%) N(10.44%) S(35.84%) 
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Molar Refractivity  = 73.50 ± 0.5 cm
3 
 
Molar Volume  = 163.3 ± 7.0 cm
3 
 
Parachor              = 469.3 ± 8.0 cm
3 
 
Index of Refraction  = 1.858 ± 0.05 
 
Surface Tension  = 68.1 ± 7.0 dyne/cm 
 
Density              = 1.64 ± 0.1 g/cm
3 
 
Dielectric Constant  = Not available 
 
Polarizability              = 29.14 ± 0.5 10
-24
cm
3 
 
Monoisotopic Mass  = 268.016261 Da 
 
Nominal Mass  = 268 Da 
 
Average Mass    = 268.423729 Da 
 
IR SPECTROSCOPY 
The samples were prepared by the KBr pellet techniques and the samples are analysed by FT-IR 
technique.  
The spectra were examined for the absence of the absence of the functional groups of the parent 
compounds and examined for the presence of vibrational absorption band for the new functional 
groups. 
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The synthetic reaction involves, the reaction between 2-amino thiophene derivative with 
glacial acetic acid, formic acid and carbondisulphide to yield pyrimidine analogues 
 
 
TABLE NO 3: IR ABSORPTION BAND  
 
ABSORPTION 
BAND 
CMG MMG MC TM 
 
 CN Stretching 
 
 NH Stretching 
 
C=N Stretching 
 
C=O Stretching 
  
 
  
 
  
 
  
 
  
 
  
 
  
 
  
 
  
 
  
 
  
 
        × 
 
  
 
  
 
  
 
  
 
  
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SAMPLE CODE: CMG       
                  
SAMPLE CODE: MC 
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SAMPLE CODE MMG 
                     
SAMPLE CODE TM 
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NMR SPECTROSCOPY  
SAMPLE CODE: MC          
 
S.NO ∆ VALUE TYPES OF PEAK NUMBER OF PROTONS 
 1. 3.01 singlet      6 
 2. 6.78 doublet      2  
 3. 7.24-7.25 multiplet      1 
 4. 7.45 singlet      1 
 5. 7.62 doublet      2 
 6. 7.75 singlet      1 
 7. 7.83-7.85 multiplet      1 
 8. 8.04-8.05 Multiplet      1 
RESULTS AND DISSCUSSION 
 
Dept. of Pharmaceutical Chemistry, COP, MMC Page 81 
 
  
SAMPLE CODE: CM 
 
S.NO ∆ VALUE TYPES OF PEAK NUMBER OF PROTONS 
   1. 7.27-7.30 multiplet 1 
   2. 7.65 singlet 2 
   3. 7.71-7.78 multiplet 2 
   4. 7.85-7.87 multiplet 1 
   5. 7.93-7.96 multiplet 1 
   6. 8.00-8.07 multiplet 1 
   7. 8.11 singlet 1 
   8. 8.13-8.15 triplet 1 
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SAMPLE CODE: MMF 
 
 
S.NO ∆ VALUE TYPES OF PEAK NUMBER OF PROTONS 
 1. 0.92 Triplet 1 
 2. 1.12-1.43 Multiplet 4 
 3. 1.61 Doublet 1 
 4. 2.34 Singlet 1 
 5. 2.66 Singlet 1 
 6. 2.70-2.72 Multiplet 1 
 7. 8.03-8.09 Multiplet 1 
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SAMPLE CODE: CMG 
 
 
 
S.NO ∆ VALUE TYPES OF PEAK NUMBER OF PROTONS 
 1. 0.82-1.05 Singlet 2 
 2. 1.25 Doublet 2 
 3. 1.35-1.38 Multiplet 5 
 4. 1.41 Singlet 1 
 5. 2.01 Singlet 1 
 6. 2.23 Doublet 1 
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GC-MS SPECTROSCOPY 
The molecular weight of  synthesized compounds are confirmed by GC-MS Analysis. 
 
TABLE NO 4: GC-MS ANALYSIS 
SAMPLE CODE CALCULATED MASS ACTUAL MASS 
            CM 192.28g/mol 
 
192.13g/mol 
            MM 224.23g/mol 
 
223.83g/mol 
            CMG 220.33g/mol 
 
220.32g/mol 
            MMG 266.27g/mol 
 
266.26g/mol 
            MMF 238.26g/mol 
 
238.62g/mol 
             MC 300.38g/mol 
 
300.37g/mol 
            CC 270.44g/mol 
 
270.44g/mol 
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SAMPLE CODE: MM 
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SAMPLE CODE:CM 
 
 
 
 
 
 
 
 
 
RESULTS AND DISSCUSSION 
 
Dept. of Pharmaceutical Chemistry, COP, MMC Page 88 
 
 
 
RESULTS AND DISSCUSSION 
 
Dept. of Pharmaceutical Chemistry, COP, MMC Page 89 
 
 
SAMPLE CODE: CC 
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SAMPLE CODE: CMG 
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SAMPLE CODE: MC 
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SAMPLE CODE: MMF 
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SAMPLE CODE: MMG 
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IN-SILICO TOXICITY PREDICTION 
     Insilico toxicity prediction was done for the filtered 7 compounds using OSIRIS Property 
Explorer. This software is available for access in the Organic Chemistry Portal. Using the 
prediction tool, mutagenicity, tumorogenicity, skin irritation and reproductive effects were 
calculated. The results were color coded. The green color represents that the compounds is non-
toxic. Yellow color indicates moderate and severe toxicity of the chemicals respectively. 
                                  TABLE NO 5: TOXICITY PREDICTION 
SAMPLE MM CM MMG MMF CMG CC MC TM 
Mutagenic 
 
   + + + + + + + + 
Tumorigenic 
 
    + + + + + + + + 
Irritant 
 
    + + + + + + + + 
Reproductive 
effect 
    + + + + + + + + 
 
 
                 
TOXICITY PREDICTION OF TM                        TOXICITY PREDICTION OF MC 
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TOXICITY PREDICTION OF CC                             TOXICITY PREDICTION OF CM 
           
TOXICITY PREDICTION OF MMG                     TOXICITY PREDICTION OF MMF 
            
TOXICITY PREDICTION OF MM                       TOXICITY PREDICTION OF CMG 
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 INSILICO SCREENING OF DRUG LIKENESS 
COMPOUND NAME: MM 
    
 
COMPOUND NAME: MMG 
   
 COMPOUND NAME: CM              
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COMPOUND NAME : CMG 
  
 
COMPOUND NAME: MMF 
  
 
COMPOUND NAME: MC 
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COMPOUND NAME: CC 
    
 
                                                 BIOLOGICAL EVALUATION 
       The anti-tubercular activities of the synthesized compounds were determined by Microplate 
Alamar Blue Assay method (MABA). The organism used in the study is Mycobacterium 
tuberculosis H37Rv 
All the synthesized compounds showed anti-mycobacterial activity in a varying degree against 
the organism tested. The organism tested was susceptible to all the synthesized compounds and 
the minimum inhibitory concentration for the compounds varied between 6.25 and 1.6 mcg/ml. 
The data pertaining to these observations are presented in the table. Inhibition was compared 
using Pyrazinamide- 3.125 mcg/ml and streptomycin- 6.25 mcg/ml as standard. 
Among the synthesized compounds, compound- MMF exhibit activity at 1.6 mcg/ml and 
compound –TM exhibit activity at 3.12 mcg/ml. 
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            TABLE NO 6: BIOLOGICAL EVALUATION OF SYNTHESIZED COMPOUNDS 
            
            
            S – SENSITIVE 
            R – RESISTANT 
S.NO SAMPLES 100µg/ml 50 
µg/ml 
25 
µg/ml 
12.5 
µg/ml 
6.25 
µg/ml 
3.12 
µg/ml 
1.6 
µg/ml 
0.8 
1. CM      S  S  S  S  S R R R 
2. MMG      S  S  S  S  R R R R 
3. MM      S  S  S  S  R R R R 
          
                     
                               SAMPLE 3: CM, SAMPLE 4: MMG, SAMPLE 5: MM  
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                                                           DISCUSSION 
The discussion of the following results given below;  
The following compounds have best docking score against specific targets and it was synthesized 
at appropriate manner , then the purity of the compounds are determined, it shows sharp melting 
point, single spot obtained in the TLC. 
Among 8 compounds, 5 of them were obtained at 95% purity. It was confirmed by GC-MS 
analysis (obtaining a single peak) and molecular weight also obtained at ± 1 variation. 
Then the functional group determination is obtained from FT-IR. It is confirmed by obtaining 
specific absorption band in the spectra. 
Molecular weights of the synthesized compounds are interpretated by NMR, depending upon the 
no of protons.    
The biological evaluation of the compounds are denoted that the specific organism was sensitive 
at 3.12 and 3.12mcg/ml and showed better activity compared to standard drugs. 
The toxicity of the compounds also showed that all the 8 compounds are non-toxic.  
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                                                                SUMMARY  
 
Glutamine synthetase 1 is a vital enzyme present in the cell wall of Mycobacterium tuberculosis 
H37Rv. It belongs to the Ligase family.  
 
This enzyme was chosen as the target for the drug design study after thorough literature review.  
A database of 200 molecules with potential to inhibit the target (PDB id: 4 ACF) was chosen by 
altering the lead molecules, amino thiophene. 
 
The designed molecules were docked against the target chosen using ARGUS LAB. 
  
From among the docked molecules, 8 molecules with good Score were chosen for laboratory 
synthesis. The drug likeness and toxicity prediction was carried out for the filtered 8 compounds 
in silico.  
 
Then further the compounds were synthesized. The reaction conditions were optimized.  
 
The compounds were labeled as MM, CM, MMF, CMG, MMG, MC, CC,TM. These compounds 
were synthesized and recrystallized.  
 
PURITY: 
 
The purity of the compounds was evaluated by sharp melting point and TLC and was 
characterized by Infrared Spectroscopy, Nuclear Magnetic Resonance Spectroscopy and MASS 
Spectroscopy. A single peak obtained from GC-MS analysis predicted that the synthesized 
compounds are formed at correct manner. The molecular weight of the compounds are also 
determined. 
 
Further, compounds are characterized by IR, NMR (H1NMR) functional groups , number of 
protons are determined respectively. 
 
All the synthesized compounds exhibited molecular ion peak (M
+ 
) of varying intensities 
ascertaining the molecular weights of the compounds. 
 
ANTI-MICROBIAL ACTIVITY 
 
The purified compounds were screened for anti-tubercular activity by invitro Micro Plate Alamar 
Blue Assay. It showed that the synthesized compounds are sensitive at 3.12- 1.6 mcg/ml level. 
So the following results concluded that the synthesized compounds have better anti-tubercular 
activity. 
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The synthesized compounds were active at 3.12-1.6 mcg/ml, which are compared to that of the 
known anti-tubercular agents, Pyrazinamide: 3.125mcg/ml, Ciprofloxacin: 3.125 and 
Streptomycin: 6.25mcg/ml  
 
 
TOXICITY PREDICTION 
The toxicity of the synthesized compounds are screened by OSIRIS, while it is non-toxic means 
it showed green color and toxic means it indicated by red. All the compounds are non-toxic and 
it showed better activity.  
 
CONCLUSION 
 
  
It is concluded that the synthesized compounds might effectively inhibit the chosen target 
Glutamine Synthetase I which is essential for the Mycobacterial Tuberculosis. Further structural 
modifications of the synthesized compounds will aid in the development of potential molecule 
against the pathogen.  
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